Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

om placebo to I.V. golimumab during the trial (P < 0.001).  Patients randomized to I.V. golimumab and those in the crossover group had a mean change in total vdH-S score of 0.15 (+/- 1.83) and 0.12 (+/- 2.44), respectively, from week 24 to 52, supporting inhibition of structural damage progression in all patients receiving I.V. golimumab.

Significant proportions of patients receiving I.V. golimumab also demonstrated improvements in signs and symptoms compared with patients receiving placebo according to ACR scores, European League Against Rheumatism (EULAR)/Disease Activity Score (DAS) 28 C-reactive protein (CRP) response criteria and Health Assessment Questionnaire (HAQ) disability scores at weeks 14 and 24.  A majority of those patients who achieved ACR 20, ACR 50, ACR 70 and EULAR/DAS 28 CRP good/moderate response by week 24 maintained response through week 52 (82 percent of ACR20 responders; 71.7 percent of ACR 50 responders; 60.9 percent of ACR 70 responders; 80 percent demonstrating DAS28-CRP good/moderate response).  The EULAR/DAS 28 CRP is a measure of disease activity in patients with RA that is calculated by assessing the number of tender and swollen joints (among a total of 28), serum CRP level (indicator of inflammation), and the patient's assessment of global health. 

Through week 52 of the GO-FURTHER trial, the safety profile of I.V. golimumab remained consistent with previously reported week 24 data.  Through week 24, adverse events (AEs) occurred in 53 percent of patients receiving I.V. golimumab and 49 percent of patients receiving placebo, and serious AEs were reported in more I.V. golimumab-treated patients (4 percent) than placebo-treated patients (2 percent).  Rates of AEs and serious AEs at week 52 among patients receiving I.V. golimumab were 65 percent and 9 percent, respectively.  There were no serious opportunistic infections through week 52 of the study.  One case of tubercul
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... SWANTON, Vt ., May 7 This May, AllerAir ... their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness tips ... www.allerair.com .  Additionally, their blogs and articles ...
... A post-hoc analysis of a Phase 3 safety study ... a lower incidence of nausea, vomiting and constipation when compared ... moderate to severe low-back or osteoarthritis pain.  These data will ... Annual Scientific Meeting of the American Pain Society (APS), and ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 2Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 4Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 5Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 6Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 7Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 8Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 9
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... 18 Smart Balance Inc.,(Nasdaq: SMBL ) announced ... the annual Citi Small/Midcap Conference in Las Vegas, NV, ... Steven Hughes, Chairman and Chief Executive Officer and Alan ... to,investors at the conference as well as through the ...
... only a few centers in Canada that perform living donor ... that expands the organ donor pool. About 80 liver transplants ... living-donor. , All potential liver transplant donors are assessed based ... liver and vascular and bile duct anatomy. Thanks to a ...
... March 18 The Comprehensive Eating,Disorders Program at ... treat young adults ages 18 to 21. This ... adolescents and college students., "I am delighted ... to our undergraduate age group," said Naomi Brown, ...
... VASCULAR BENEFITS FROM EXERCISE , Overweight but active ... in a first-of-its kind study from Indiana University that ... , Vascular function is important because of its ... saw an average 24 percent improvement in their vascular ...
... 80 and older may not need to be hospitalized, ... People over 80 can safely have diagnostic radiology tests ... for their safety, a new study finds. , "The ... but also drug trials, might not be safe for ...
... ACM, one of the country,s leading,healthcare ... Plans, Inc. today announced a new agreement ... pricing precision to medical,pharmacy infusion services provided ... a decade, ACM,s e-Precision Claims(SM) technology has ...
Cached Medicine News:Health News:Smart Balance to Webcast Presentation at Citi Small/Midcap Conference 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 3Health News:IU Health & Wellness: Research and insights from Indiana University 2Health News:IU Health & Wellness: Research and insights from Indiana University 3Health News:IU Health & Wellness: Research and insights from Indiana University 4Health News:The Elderly Can Be Candidates for Angioplasty, Stenting 2Health News:ACM Partners With Tufts Associated Health Plans to Improve the Cost-effective Delivery of Home Infusion Services 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: